The emergence of multidrug-resistant bacteria has created an urgent need for antibiotics with a novel mechanism of action. The bacterial cell division protein FtsZ is an attractive target for the development of novel antibiotics. The benzo[c]phenanthridinium sanguinarine and the dibenzo[a,g]quinolizin-7-ium berberine are two structurally similar plant alkaloids that alter FtsZ function. The presence of a hydrophobic functionality at either the 1-position of 5-methylbenzo[c]phenanthridinium derivatives or the 2-position of dibenzo[a,g]quinolizin-7-ium derivatives is associated with significantly enhanced antibacterial activity. 3-Phenylisoquinoline represents a subunit within the ring-systems of both of these alkaloids. Several 3-phenylisoquinolines and 3-phenylisoquinolinium derivatives have been synthesized and evaluated for antibacterial activity against Staphylococcus aureus and Enterococcus faecalis, including multidrug-resistant strains of methicillin-resistant S. aureus (MRSA) and vancomycin-resistant E. faecalis (VRE). A number of derivatives were found to have activity against both MRSA and VRE. The binding of select compounds to S. aureus FtsZ (SaFtsZ) was demonstrated and characterized using fluorescence spectroscopy. In addition, the compounds were shown to act as stabilizers of SaFtsZ polymers and concomitant inhibitors of SaFtsZ GTPase activity. Toxicological assessment of select compounds revealed minimal cross-reaction mammalian b-tubulin as well as little or no human cytotoxicity.
Introduction
Infections associated with methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE) represent a serious nosocomial health concern for both patients and healthcare professionals. 1, 2 Antibacterial agents with novel mechanisms of action represent a critical need in light of the increased incidence of bacterial resistance to current clinical agents. FtsZ is a key bacterial protein involved in microbial cell division (cytokinesis). 3, 4 It is highly conserved among bacterial pathogens and, in several genetic studies, has been shown to be essential for bacterial viability. [5] [6] [7] [8] Cell division in bacteria occurs at the site of formation of a cytokinetic Z-ring polymeric structure comprised of FtsZ subunits. 9 The vital role that FtsZ plays in bacterial cell division makes this protein a promising therapeutic target. FtsZ-targeting antibacterial agents can exert their disruptive effects on the Z-ring by either stabilizing FtsZ polymers or inhibiting their formation. [14] [15] [16] [17] [18] [19] [20] [21] Recent advances in the development of small molecules that target FtsZ have been the subject of several recent reviews. [10] [11] [12] [13] [22] [23] [24] The benzo[c]phenanthridine sanguinarine (1) and the dibenzo[a,g]quinolizin-7-ium berberine (3) (Fig. 1 ) are antibacterial plant alkaloids (albeit a weak antibacterial in the case of berberine) that have been identified as small molecules that alter FtsZ Z-ring formation and FtsZ function. 15, 16, 22, 25 In addition, the presence of a hydrophobic functionality at either the 1-position of benzo [c] phenanthridines, as in 4, or at the 2-position of dibenzo[a,g]quinolizin-7-ium derivatives, as in 5, significantly enhances antibacterial activity. [26] [27] [28] 3-Phenylisoquinoline represents a flexible subunit of the scaffold associated with the core structure of each of the compounds illustrated in Figure 1 . We report, herein, the synthesis and relative antibacterial activity of several 3-phenylisoquinolines and 3-phenylisoquinolinium derivatives. As the constitutively charged quaternary isoquinolinium derivatives uniformly exhibited enhanced antibacterial activity relative to their non-quaternary isoquinoline precursors, we also explored the effect of varied basic functionalities at the 1-position.
Chemistry
3-Bromo-6,7-dimethoxyisoquinolin-1-one was prepared from 5,6-dimethoxy-1-indanone as previously described in the literature. 29 Suzuki-coupling of this intermediate with [1,1 0 ]-biphenyl-3-ylboronic acid provided 3-[ [1, 1 0 ]-biphenyl-3-yl]-6,7-dimethoxyisoquinolin-1-one, which was converted to 1a, 8a-11a or 14a as outlined in Scheme 1. Alternatively, 3-bromo-6,7-dimethoxyisoquinolin-1-one was used in a Suzuki-coupling with 3(t-butyl) phenyl boronic acid to provide the intermediate for ultimately preparing 17a. Both 1b and 9b were prepared by reacting either 1a or 9a, respectively, with methyl iodide. The 2-guanidinoethyl derivatives 15a and 20a were prepared from the primary amines, 14a and 17a by reaction with 1,3-di-Boc-2-(trifluoromethylsulfonyl)guanidine followed by removal of the Boc-protecting groups with trifluoroacetic acid.
6,7-Dimethoxy-3-hydroxy-1-methylisoquinoline and 6,7,8-trimethoxy-3-hydroxy-1-methylisoquinoline were used for the preparation of 2a-4a as outlined in Scheme 2. Both of these 3-hydroxy-1-methylisoquinolines were prepared from either 3,4-dimethoxyphenyl acetic acid or 3,4,5-trimethoxyphenyl acetic acid as described in the literature. 30 Formation of their triflates and subsequent reaction with either [1,1 0 ]-biphenyl-3-ylboronic acid or 3-(t-butyl) phenyl boronic acid provide the appropriately substituted 3-phenyl-1-methylisoquinoline, which was treated with methyl iodide to provide 2b-4b. Bromination of 2a with NBS provided the bromomethyl derivative used to prepare 12a. Similarly, bromination of 4a provided its bromomethyl derivative, which was subsequently used to form 16a and 18a.
The preparation of 6a,b is outlined in Scheme 3. The triflate of 6,7,8-trimethoxy-3-hydroxy-1-methylisoquinoline was coupled with 2-benzyloxy-3,4-dimethoxyphenylboronic acid. Removal of the benzyloxy group, followed by formation of the triflate of the resulting phenol and Suzuki-coupling with [1, 1 0 ]-biphenyl-3-ylboronic acid provided 6a, which was treated with methyl iodide to give 6b.
The preparation of 12a and the 1-guanidinomethyl derivatives 13a and 19a is illustrated in Scheme 4. Compounds 2a and 4a were oxidized to their 1-formyl derivatives with SeO 2 , which could then be reduced to their respective benzyl alcohols with NaBH 4 . Treatment with 1,3-bis(t-butoxycarbonyl)guanidine and subsequent removal of the N-Boc-protecting groups with TFA provided the guanidinomethyl derivatives 13a and 19a. Compound 12a was prepared by reaction of 3-([1,1-biphenyl]-3-yl)-6,7-dimethoxy-1-hydroxymethylisoquinoline with diphenylphosphorylazide to form the azide intermediate, which was reduced to the 1-aminomethyl derivative using polymer supported triphenylphosphine.
Method used for 5a,b, 7a,b, and 21a are illustrated in Scheme 5. Using the triflate of 6,7-dimethoxy-3-hydroxy-1-methylisoquinoline, an initial Suzuki-coupling with 3-hydroxyphenylboronic acid provided 6,7-dimethoxy-3-(3-hydroxyphenyl)-1-methylisoquinoline, which served as a versatile intermediate for the formation of these compounds. This intermediate was converted to its triflate and then subjected to a second Suzuki-coupling with 4-biphenylboronic acid or 4-t-butylphenylboronic acid provided 5a and 7a, respectively. Both 5a and 7a were converted to the quaternary ammonium derivatives by treatment with methyl iodide at 100°C in a sealed tube. The 1-methyl substituent of 7a was oxidized to its 1-formyl derivative with SeO 2 , reduced with sodium borohydride to the 1-hydroxymethyl intermediate, which under Mitsunobu reaction conditions provided the bis-(N-Boc guanidine). Treatment of this compound with trifluoroacetic acid provided 21a. 
Pharmacology
The relative antistaphylococcal and antienterococcal activities of the 3-phenylisoquinoline and 3-phenylisoquinolinium derivatives synthesized are summarized in Table 1 . No significant antibiotic activity was observed for the non-quaternary derivatives 1a-7a against either S. aureus or E. faecalis. Antibacterial activity was observed for N-methyl quaternary ammonium derivatives 1b-7b against S. aureus. Antibacterial potency increased with the increased lipophilicity of the substituent at the 3 0 -position. With the exception of 1b and 7b, there were relatively minor differences in the MICs observed with methicillin-sensitive S. aureus (MSSA) relative to methicillin-resistant S. aureus (MRSA). The MICs observed with vancomycin-sensitive E. faecalis (VSE) did tend to be greater than those observed with MSSA. Against vancomycin-resistant E. faecalis (VRE), only 5b, 6b, and 7b had MICs within the range of 4-8 lg/mL. We evaluated a series of 3-(3 0 -phenyl)phenylisoquinoline derivatives with varied substituents at the 1-position. Among the 1-amino-3-(3 0 -phenyl)phenylisoquinolines 8a, 9a and 9b, only the quaternary ammonium derivative 9b exhibited modest activity against S. aureus, but was not significantly active against either strain of E. faecalis. The 1-guanidino derivative 10a was active against both sensitive and resistant strains of both S. aureus and E. faecalis. These data suggest that the presence of a basic substituent at the 1-position that would exist as a protonated species under physiological conditions is associated with antibacterial activity. This structure-activity is further substantiated by the observation that the 1-cyano derivative is inactive, while its reduction product, the aminomethyl derivative 12a is active against S. aureus. The 1-guanidinomethyl-and 1-(2-guanidinoethyl)-derivatives 13a and 15a are active against both strains of S. aureus and E. faecalis. The less basic 1-(2-aminoethyl) derivative, 14a, is active against both strains of S. aureus, but is only modestly active against the vancomycin-sensitive strain of E. faecalis. Compound 21a is analogous to 13a, having a t-butyl substituent at its 4 00 -position. In general, the addition of this t-butyl group results in 21a exhibiting slightly less antibacterial activity than 13a.
The results observed for a series of 3-(3 0 -t-butyl)phenylisoquinolines indicate that the 1-aminomethyl analog 16a has greater potency than the 1-(2-aminoethyl) derivative 17a. This differs from the trend observed with the 3-(3-biphenyl)isoquinolines. The more basic amidinomethyl derivative 18a and the guanidinomethyl derivative 19a are modestly more active than 17a in both strains of S. aureus, while the guanidinomethyl derivative 19a had comparable activity to 16a. The guanidinoethyl derivative 20a is the more active of 3-(3 0 -t-butyl)phenylisoquinolines against MRSA. Compounds 17a-20a have similar activity against VRE and VSE and were only slightly more active than 16a.
While sanguinarine and chelerythrine have significant antibacterial activity against MSSA and MRSA, berberine has much weaker potency against these S. aureus strains. Against both strains of E. faecalis, chelerythrine and berberine do not have remarkable antibacterial activity. Only sanguinarine has comparable activity against both sensitive and resistant strains of both S. aureus and E. faecalis to several of the more potent isoquinoline derivatives evaluated in this study.
Biochemistry

Binding of the isoquinolines to S. aureus FtsZ (SaFtsZ)
We sought to determine whether the antibacterial activity of the 3-phenyl substituted isoquinolines might reflect a corresponding ability of the compounds to target bacterial FtsZ. As a first step toward this end, we explored the potential of the active compounds to bind purified S. aureus FtsZ (SaFtsZ). Specifically, we monitored the intrinsic fluorescence of the compounds as a function of added SaFtsZ. Figure 2 shows representative results for two of the more active compounds (5b and 7b). Note that increasing SaFtsZ concentrations increase the fluorescence emission intensities of both compounds, while also blue-shifting the maximum spectral wavelength by 4-6 nm ( Fig. 2A and B) . These FtsZinduced changes in compound fluorescence are indicative of compound binding to the target protein.
We determined compound-FtsZ dissociation constants (K d ) for the binding reactions by analyzing the FtsZ-induced changes in compound fluorescence with the following 1:1 binding formalism:
In this relationship, I 0 and I are the fluorescence emission intensities of the compound in the absence and presence of protein, respectively; I 1 is the fluorescence emission intensity of the compound in the presence of an infinite protein concentration; and [C] tot and [P] tot are the total concentrations of compound and protein, respectively. The 1:1 binding formalism yielded excellent fits (R 2 >0.99) of the 5b and 7b fluorescence intensity profiles (the solid lines in Fig. 2C and D) . The K d values obtained from these fits were similar in magnitude (2.0 ± 0.7 lM for 5b and 5.4 ± 1.5 lM for 7b). Significantly, these K d values are also similar in magnitude to the corresponding MIC values of the two compounds versus MSSA (MIC = 1 lg/mL = 2.2 lM for 5b and 2.3 lM for 7b).
Impact of the isoquinolines on SaFtsZ polymerization
We next sought to explore whether the binding of the isoquinoline compounds to FtsZ had an impact on the self-polymerization activity of the protein. In this connection, we utilized a microtiter plate-based light scattering (turbidity) assay in which FtsZ polymerization is detected in solution by a time-dependent increase in light scattering, as reflected by a corresponding increase in solution absorbance at 340 nm (A 340 ). When tested at a concentration of 40 lg/mL, all active isoquinoline compounds with MIC values 616 lg/mL (Table 1) were found to stimulate SaFtsZ polymerization, with the time-dependent A 340 profiles acquired in the presence of DMSO vehicle and seven of the active compounds (5b, 7b, 15a, 17a, 18a, 19a, and 20a) being shown in Figure 3A as illustrative examples. This behavior is similar to that previously reported for the FtsZ-targeting benzamide analog PC190723 14, 18 and recapitulated here as a positive control (Fig. 3B) . We used the nonFtsZ-targeting drug vancomycin as a negative control in these studies. As expected, vancomycin had no impact on the polymerization of SaFtsZ (Fig. 3B ). Similar to vancomycin, and in striking contrast to the active isoquinolines, the inactive isoquinoline compounds (with MIC values >64 lg/mL) did not significantly impact SaFtsZ polymerization, as exemplified by the similar A 340 profiles acquired in the presence of vehicle and two of the inactive compounds (4a and 7a) at an equivalent concentration of 40 lg/mL (Fig. 3A) . Thus, the SAR of the isoquinolines with regard to antistaphylococcal activity correlates well with the corresponding SAR observed for stimulation of SaFtsZ polymerization. As an additional comparator in these assays, we also included the natural plant alkaloid berberine (3), which is inactive versus S. aureus at concentrations 664 lg/mL (Table 1) . Like the inactive isoquinolines, berberine did not significantly impact SaFtsZ polymerization at an equivalent concentration of 40 lg/mL (Fig. 3B ).
We further investigated whether the stimulatory impact of the active isoquinolines on SaFtsZ polymerization was dependent on compound concentration. Figure 3C illustrates the A 340 results obtained in the presence of vehicle and compound 20a at concentrations of 20, 30, and 40 lg/mL. Note that the extent to which 20a enhances SaFtsZ polymerization increases with increasing compound concentration. We observed a similar concentration-dependent behavior with the other active isoquinolines (not shown). As a negative control, Figure 3C also shows the A 340 profile of 40 lg/mL 20a in the absence of FtsZ. The lack of A 340 change associated with the compound alone confirms that the enhanced light scattering induced by 20a in the presence of FtsZ reflects a corresponding stimulation of FtsZ self-polymerization and not simply non-specific compound aggregation or precipitation.
We next explored the stability of the SaFtsZ polymers induced by the active isoquinolines. In the absence of a polymer-stabilizing agent or compound, addition of GDP has been shown to depolymerize FtsZ polymers formed in the presence of GTP. 14 We, therefore, sought to determine the impact, if any, of added GDP (1 mM) on the SaFtsZ polymers formed in the presence of both GTP (1 mM) and the active isoquinolines (40 lg/mL). Figure 3D shows the results for compounds 7b, 17a, and 20a as illustrative examples. Note that addition of 1 mM GDP does not exert a significant impact on the A 340 signal, an observation indicating that SaFtsZ polymers induced by the presence of the isoquinoline compounds are stable to the depolymerizing effects of GDP. This behavior is similar to that previously reported for FtsZ-targeting antibacterial compound PC190723 and the FtsZ protein of Bacillus subtilis. 14 Viewed as a whole, our polymerization results are consistent with the antibacterial activities of the isoquinolines being related, at least in part, to their stabilizing actions on FtsZ polymerization.
Impact of the isoquinolines on SaFtsZ GTPase activity
We investigated the impact, if any, of the active isoquinolines on the GTPase activity of SaFtsZ. Table 2 summarizes the results for identical concentrations (40 lg/mL) of the seven active compounds (5b, 7b, 15a, 17a, 18a, 19a, and 20a) used in the SaFtsZ polymerization profiles shown in Figure 3A . Note that the isoquinoline compounds inhibit the GTPase activity of SaFtsZ by as much as 85%, in marked contrast to the non-FtsZ-targeting drug vancomycin, which has no significant impact. This inhibitory activity is consistent with that previously observed for the FtsZ polymer-stabilizing compound PC190723 versus both B. subtilis and S. aureus FtsZ. 14, 18, 32 An analysis of the concentration dependence with which the active isoquinolines 15a and 18a inhibit the GTPase activity of SaFtsZ reveals that both compounds stimulate GTPase activity at lower concentrations, followed by inhibition at higher concentrations, a behavior similar to that previously reported for PC190723 and B. subtilis FtsZ. 14 It has been suggested that the increase in FtsZ GTPase activity in the presence of low compound concentrations may simply reflect a polymerization-induced enhancement in GTPase activity relative to that associated with the polymerization of the protein in the absence of added compound (see Fig. 4 ). on the polymerization of b-tubulin porcine tubulin using an assay similar to that described above for SaFtsZ polymerization. We used the antineoplastic drugs paclitaxel (taxol) and nocodazole as positive controls in these assays. Paclitaxel is a known stimulator of tubulin polymerization and nocodazole is a known inhibitor of tubulin polymerization. [33] [34] [35] Figure 5 shows the time-dependent 
Cytotoxicity of the isoquinolines
The non-quaternized isoquinoline derivatives that exhibited significant antibacterial activity did tend to have better solubility properties than the quaternary ammonium derivatives. In addition, it would be expected that these derivatives would be more efficiently absorbed and distributed. Several of these non-quaternized 6,7-dimethoxyisoquinoline derivatives were evaluated for cytotoxicity against mammalian cells. Among the compounds that were evaluated were 10a, 12a, 13a, 15a-17a, and 19a-21a. These data indicate that there is no clear correlation between the observed cytotoxicity to mammalian cells, as reflected in their IC 50 values, and the observed antibacterial activity as reflected by their MICs (IC 90 values). For 13a, 15a, 16a, 19a-21a, no significant human cell toxicity was observed at the highest concentration tested (10 lM) in HEK293 cells. Compound 12a did exhibit modest human cell toxicity with an IC 50 value of 3.0 lM in HEK293 cells, but was less toxic to canine MDCK cells with (IC 50 = 7.0 lM). The more toxic derivatives of these 6,7-dimethoxyisoquinoline derivatives were 10a and 17a which had IC 50 values that ranged from 2.2 to 3.5 lM in these cells.
Conclusions
The data indicate that various 3-phenylisoquinolines and 3-phenylisoquinolinium derivatives can exhibit significant antibacterial activity against methicillin-sensitive S. aureus (MSSA) and methicillin-resistant S. aureus (MRSA). The presence of a basic substituent at the 1-position among the 3-phenylisoquinoline derivatives was associated with increased antibacterial activity. Several 3-phenylisoquinolinium derivatives such as 13a-15a, 20a, and 21a have MIC values that range from 2 to 4 lg/mL against MSSA and MRSA. Few of these compounds exhibited potent antibacterial activity against VRE. However, 10a, 13a, and 15a each has a MIC against VRE of 8 lg/mL, which is significantly lower than that observed for all of the clinical control compounds evaluated (MICs >64 lg/mL).
Formation of the N-methylisoquinolinium derivatives of those compounds that did not have a functional group at the 1-position that could be protonated at physiological pH increased antibacterial activity in each instance. In general the more lipophilic compounds, such as 3-(3 0 -biphenyl)isoquinoline or 3-3 0 -terphenyl)isoquinoline, exhibited the greater antibacterial activity. Several quaternary ammonium derivatives, 5b, 6b, and 7b had MICs of 1 lg/mL against MSSA and 1-8 lg/mL against MRSA. Compounds 5b, 6b, and 7b have MIC values that range from 4 to 8 lg/mL, which is lower than the MICs observed for the clinical compounds evaluated in this study.
In vitro studies with purified SaFtsZ suggest that the antibacterial activity of the compounds may be related to their stabilizing impact on FtsZ polymerization. Importantly, however, the compounds do not impact the polymerization dynamics of mammalian tubulin to any significant degree. Several of the non-quaternized isoquinoline derivatives in this study were also shown not to be highly toxic to mammalian cells. This degree of target specificity bodes well for desirable toxicological profiles on the part of the more active compounds that may have beneficial physicochemical and pharmacokinetic properties. 
3-Bromo-6,7-dimethoxyisoquinolin-1(2H)-one (550 mg, 1.94 mmol) was combined with 3-biphenyl boronic acid (768 mg, 3.88 mmol), Pd(OAc) 2 (43.5 mg, 0.194 mmol), XPhos (185 mg, 0.388 mmol), and K 2 CO 3 (1.07 g, 7.76 mmol) in a flask and degassed. ACN (15 mL) and H 2 O (7.5 mL) were then added and solution was heated at 100°C for 1.5 h. Reaction mixture was cooled to RT then diluted with EtOAc and washed with NaHCO 3 . Organic layer was dried over sodium sulfate and concentrated. Chromatography achieved using ISCO max gradient 70% EtOAc/hexane yielding product as a white solid (540 mg, 78% yield); mp 229-231°C; 
3-(
-dimethoxyisoquinoline (60 mg, 0.16 mmol) was dissolved in EtOH (5 mL) and Pd/C (10%, 20 mg) was added. Flask was then degassed to remove air and reaction was then stirred under an H 2(g) atmosphere overnight at RT. Catalyst was then filtered out and solvent evaporated. Chromatography achieved using ISCO max gradient 70% EtOAc/hexane yielding product as a beige oil (18 
-dimethoxyisoquinoline (9 mg, 0.026 mmol) and MeI (1 mL) were heated in a sealed tube overnight at 100°C. Solvent was then evaporated and residue was taken back up in DCM. Ether was then used to crash out solid which was filtered and dried to yield product as a tan solid (13 (2) 7.3.1. 6,7-Dimethoxy-1-methylisoquinolin-3-yl trifluorometha nesulfonate 6,7-Dimethoxy-1-methylisoquinolin-3-ol (540 mg, 2.47 mmol) and Et 3 N (0.7 mL, 4.94 mmol) in DCM were cooled to À78°C. Tf 2 O (0.5 mL, 2.96 mmol) was slowly added to the mixture and was stirred for 30 min at À78°C. Reaction was then quickly diluted with additional DCM and washed with saturated NaHCO 3 . Organic layer was dried over sodium sulfate and concentrated. Chromatography achieved using ISCO max gradient 30% EtOAc/hexane yielding product as a white solid (737 mg, 85% yield); mp 142-142°C; (4) 7.5.1. 3-(3-(t-Butyl)phenyl)-6,7-dimethoxy-1-methylisoquino line (4a) 6,7-Dimethoxy-1-methylisoquinolin-3-yl trifluoromethanesulfonate (7.3.1) (300 mg, 0.85 mmol), 3-t-butylphenylboronic acid (183 mg, 1.02 mmol), Pd(OAc) 2 (19 mg, 0.09 mmol), XPhos (81 mg, 0.17 mmol), and K 2 CO 3 (354 mg, 2.55 mmol) were combined in a flask with dioxane (9 mL) and H 2 O (3 mL) and degassed. Reaction mixture was then refluxed at 100°C for 2 h. Solution was cooled to RT then diluted with EtOAc and washed with saturated NaHCO 3 . Organic layer was dried over sodium sulfate and concentrated. Chromatography achieved using ISCO max gradient 40% EtOAc/hexane yielding product as a clear oil (245 mg, 83% yield); 7.5.2. 3-(3-(t-Butyl)phenyl)-6,7-dimethoxy-1,2-dimethylisoqui nolin-2-ium iodide (4b) 3-(3-(t-Butyl)phenyl)-6,7-dimethoxy-1-methylisoquinoline (23.5 mg, 0.07 mmol) was heated in MeI (0.5 mL) in a sealed tube overnight at 100°C. Solvent was then evaporated and residue was taken back up in DCM. Ether was then used to crash out solid which was filtered and dried to yield product as an off-white solid (23 
3-(3-(Benzyloxy)-4,5-dimethoxyphenyl)-6,7,8-trimethoxy-1-methylisoquinoline
A flask containing 6,7,8-trimethoxy-1-methylisoquinolin-3-yl trifluoromethanesulfonate (1.7 g, 4.46 mmol), (3-(benzyloxy)-4,5-dimethoxyphenyl)boronic acid (1.54 g, 5.35 mmol), K 2 CO 3 (1.54 mg, 11.2 mmol), and XPhos (212 mg, 0.45 mmol) in ACN (20 mL) and H 2 O (10 mL) was degassed and then Pd(OAc) 2 (50 mg, 0.22 mmol) was added. The resulting solution was carefully degassed again. Reaction was then heated at 90°C for 4 h. After cooling to RT, the reaction mixture was diluted with EtOAc and washed with saturated NaHCO 3 followed by brine. Organic layer was collected, dried over sodium sulfate, and concentrated. Chromatography achieved using ISCO max gradient 20% EtOAc/ hexane yielding product as a light yellow oil (2.03 g, 96% yield); 
-dimethoxy-1-methylisoquinoline (15 mg, 0.036 mmol) was heated in MeI (0.5 mL) in a sealed tube overnight at 100°C. Solvent was then evaporated and residue was taken back up in DCM. Ether was then used to crash out solid which was filtered and dried to yield product as a tan solid (15 
PdII) (t-buXPhos precatalyst) (4 mg, 0.0053 mmol) were combined in a flask and air was evacuated and replaced with N 2 . Methylamine (2 M in THF) (2 mL) followed by LHMDS (1 M in THF) (0.02 mL, 0.08 mmol) was then added, and reaction was allowed to stir overnight at RT. Reaction mixture was then diluted with EtOAc and washed with NH 4 Cl. Organic layer was dried over sodium sulfate and concentrated. Chromatography achieved using ISCO max gradient 50% EtOAc/hexane yielding product as a clear oil (20 mg (9) 7.10.
2) (20 mg, 0.053 mmol) and chloro(2-di-t-butylphosphino-2 0 ,4 0 ,6 0 -tri-i-propyl-1,1 0 -biphenyl)[2-(2-aminoethyl)phenyl]PdII) (t-buXPhos precatalyst) (4 mg, 0.0053 mmol) were combined in a flask and air was evacuated and replaced with N 2 . Dimethylamine (2 M in THF) (2 mL) followed by LHMDS (1 M in THF) (0.02 mL, 0.08 mmol) was then added, and reaction was allowed to stir overnight at RT. Reaction mixture was then diluted with EtOAc and washed with NH 4 Cl. Organic layer was dried over sodium sulfate and concentrated. Chromatography achieved using ISCO max gradient 40% EtOAc/hexane yielding product as a tan oil (20 
-dimethoxy-N,N-dimethylisoquinolin-1-amine (28 mg, 0.073 mmol) was heated in MeI (0.5 mL) in a sealed tube overnight at 100°C. Solvent was then evaporated and residue was taken back up in DCM. Ether was then used to crash out solid which was filtered and dried to yield product as a tan solid (20 
Guanidine HCl (38 mg, 0.4 mmol) was added to a suspension of NaH 60% dispersion in mineral oil (10 mg, 0.4 mmol) in anhydrous DMSO (5 mL). Reaction was heated at 60°C for 30 min then 3-([1,1 0 -biphenyl]-3-yl)-1-chloro-6,7-dimethoxyisoquinoline (7.2.2) (50 mg, 0.13 mmol) and chloro (2- 
PdII) (t-buXPhos precatalyst) (9 mg, 0.013 mmol) were then quickly added, and the reaction was heated at 100°C overnight. Reaction mixture was cooled to RT, diluted with EtOAc, and washed with H 2 O. Organic layer was dried over sodium sulfate and concentrated. Chromatography achieved using ISCO max gradient 5% MeOH/DCM yielding product as a tan solid (20 mg, 38%); mp 255-257°C; 
2) (50 mg, 0.13 mmol) and CuCN (24 mg, 0.27 mmol) in DMSO (2 mL) were heated at 140°C for 3 h. Reaction mixture was then cooled to RT, diluted with EtOAc, and washed with H 2 O. Organic layer was dried over sodium sulfate and concentrated. Chromatography achieved using ISCO max gradient 30% EtOAc/hexane yielding product as a beige solid (13 mg, 27% yield); mp 171-174°C; 39 (m, 3H), 7.34-7.30 (m, 1H) (12) 7.13. 
-dimethoxyisoquinoline-1-carbaldehyde (160 mg, 0.43 mmol) in ethanol (7 mL) was treated slowly with NaBH 4 (50 mg, 1.302 mmol)) at RT. Reaction was stirred for 1 h then acetone (2 mL) was added and solution was filtered through filter paper. Filtrate was concentrated then re-dissolved in DCM and washed with H 2 O. Organic layer was dried over sodium sulfate and concentrated. Chromatography achieved using ISCO max gradient 50% EtOAc/hexane yielding product as a yellow solid (98 mg, 61% yield); mp 164-165°C; Found 372.1587.
-dimethoxyisoquinolin-1-yl)methanol (90 mg, 0.24 mmol) in anhydrous THF (5 mL) was cooled to 0°C. Diphenylphosphorylazide (0.21 mL, 0.97 mmol) was then added followed by drop wise addition of DBU (0.15 mL, 0.97 mmol). Reaction was kept stirring at 0°C for 4 h then allowed to warm to RT overnight. Reaction mixture was then poured into 0.5 N HCl and extracted with EtOAc. Organic layer was washed with brine, dried over sodium sulfate, and concentrated. Chromatography achieved using ISCO max gradient 30% EtOAc/hexane yielding product as a clear oil (75 mg, 78% yield); Found 397.1650.
-dimethoxyisoquinoline (70 mg, 0.18 mmol) was combined in a flask with polymer supported (3 mmol/g loading) PPh 3 (88.5 mg, 0.26 mmol), THF (3 mL), and H 2 O (0.3 mL). Reaction was stirred overnight at RT. Resin was then filtered off and filtrate concentrated. Chromatography achieved using silica column max gradient 10% MeOH/ DCM/0.1% NH 4 OH yielding product as a tan oil (60 mg, 92% yield); 0 -Biphenyl]-3-yl)-6,7-dimethoxyisoquinolin-1-yl)methanol (7.13.2) (30 mg, 0.081 mmol), PPh 3 (32 mg, 0.12 mmol), and 1,3-bis(t-butoxycarbonyl)guanidine (42 mg, 0.162 mmol) in anhydrous toluene (3 mL) at 0°C was added diisopropylazodicarboxylate (0.024 mL, 0.12 mmol) drop wise over 15 min. Reaction was stirred for 3 h at RT then 2 drops H 2 O were added, and the solution was concentrated. Solid was then dissolved in DCM and passed through silica column and resulting crude product was then re-dissolved in anhydrous DCM (1.5 mL) and cooled to 0°C. TFA (1.5 mL) was then added. Reaction was taken off ice bath and stirred at RT for 2 h then solvents were evaporated. Solid was then taken back up in DCM and precipitate was filtered off yielding product as a white solid (40 mg, 93% yield over 2 steps); mp 210-213°C; 1 
To a cooled solution of t-butyl (2-(3-([1,1 0 -biphenyl]-3-yl)-6,7-dimethoxyisoquinolin-1-yl)ethyl)carbamate (166 mg, 0.34 mmol) in anhydrous DCM (1.5 mL) was added trifluoroacetic acid (1.5 mL). Reaction was taken off ice bath and stirred at RT for 2 h then solvents were evaporated. Chromatography achieved using ISCO max gradient 10% MeOH/DCM yielding product as a tan fluffy solid (131 mg, quantitative); mp 187-189°C; 
To a cooled solution of 1,
(80 mg, 0.12 mmol) in anhydrous DCM (2 mL) was added trifluoroacetic acid (2 mL). Reaction was taken off ice bath and stirred at RT for 2 h then solvents were evaporated. Chromatography achieved using ISCO max gradient 10% MeOH/DCM yielding product as a white solid (36 mg (17) 7.18.1. 3-(3-(t-Butyl)phenyl)-6,7-dimethoxyisoquinolin-1(2H)-one 3-Bromo-6,7-dimethoxyisoquinolin-1(2H)-one (300 mg, 1.06 mmol) was combined with 3-t-butylphenyl boronic acid (226 mg, 1.27 mmol), Pd(OAc) 2 (24 mg, 0.11 mmol), XPhos (100 mg, 0.21 mmol), and K 2 CO 3 (437 mg, 3.17 mmol) in a flask and degassed. ACN (9 mL) and H 2 O (3 mL) were then added and solution was heated at 100°C for 2 h. Reaction mixture was cooled to RT then diluted with EtOAc and washed with NaHCO 3 . Organic layer was dried over sodium sulfate and concentrated. Chromatography achieved using ISCO max gradient 70% EtOAc/hexane yielding product as a white solid (276 mg, 78% yield); mp 211-214°C; 1-(Bromomethyl)-3-(3-(t-butyl)phenyl)-6,7-dimethoxyisoquinoline (7.17.1) (25 mg, 0.06 mmol), acetamidine HCl (7 mg, 0.072 mmol), and K 2 CO 3 (17 mg, 0.12 mmol) in anhydrous DMF (2 mL) were heated at 50°C for 2 h. Reaction mixture was then cooled to RT, diluted with EtOAc, and washed with 10% LiCl solution. Organic layer was dried over sodium sulfate and concentrated. Chromatography achieved using ISCO max gradient 10% MeOH/DCM yielding product as an off-white solid (18 mg 
2-((3-(3-(t-Butyl
)phenyl)-6,7-dimethoxyisoquinolin-1-yl)methyl)guanidine (19a) (3-(3-(t-Butyl)phenyl)-6,7-dimethoxyisoquinolin-1-yl)methanol (50 mg, 0.14 mmol), PPh 3 (56 mg, 0.21 mmol), and 1,3-bis(tbutoxycarbonyl)guanidine (74 mg, 0.28 mmol) in anhydrous toluene (4 mL) at 0°C was added diisopropylazodicarboxylate (0.04 mL, 0.21 mmol) drop wise over 15 min. Reaction was stirred for 3 h at RT then 2 drops H 2 O were added, and the solution was concentrated. Solid was then dissolved in DCM and passed through silica column and resulting crude product was then re-dissolved in anhydrous DCM (1.5 mL) and cooled to 0°C. TFA (1.5 mL) was then added. Reaction was taken off ice bath and stirred at RT for 2 h then solvents were evaporated. Chromatography achieved using ISCO max gradient 10% MeOH/DCM yielding product as an off-white solid (52 mg, 93% yield over two steps); mp 194-196°C; 1 (20) 7.21.1. 1,3-di-Boc-2-(2-(3-(3-(t-butyl)phenyl)-6,7-dimethoxyi soquinolin-1-yl)ethyl)guanidine 2-(3-(3-(t-Butyl)phenyl)-6,7-dimethoxyisoquinolin-1-yl)ethanamine (7.18.4) (67 mg, 0.18 mmol), 1,3-di-Boc-2-(trifluoromethylsulfonyl)-guanidine (86 mg, 0.22 mmol), and Et 3 N (0.03 mL, 0.22 mmol) in anhydrous DCM (5 mL) were stirred for 1 h at 37°C. Reaction mixture was then diluted with DCM and washed with NaHCO 3 . Organic layer was dried over sodium sulfate and concentrated. Chromatography achieved using ISCO max gradient 40% EtOAc/hexane yielding product as a clear oil (75 mg, 67% To a cooled solution of 1,3-di-Boc-2-(2-(3-(3-(t-butyl)phenyl)-6,7-dimethoxyisoquinolin-1-yl)ethyl)guanidine (53 mg, 0.087 mmol) in anhydrous DCM (1 mL) was added trifluoroacetic acid (1 mL). Reaction was taken off ice bath and stirred at RT for 2 h then solvents were evaporated. Chromatography achieved using ISCO max gradient 10% MeOH/DCM yielding product as a tan fluffy solid (36 To a solution of (3-(4 0 -(t-butyl)-[1,1 0 -biphenyl]-3-yl)-6,7-dimethoxyisoquinolin-1-yl)methanol (39 mg, 0.091 mmol), PPh 3 293 (HEK293) cell line was provided by Dr. Zue-Hung Hsu (formerly at Columbia University, presently at Beijing National academy). The Madin-Darby Canine Kidney (MDCK) epithelial cells were obtained from Professor Patrick Sinko (Rutgers University). The cytotoxicity assay was performed using 96-well microtiter plates. Cells were grown in suspension at 37°C in 5% CO 2 and maintained by regular passage in DMEM media. For determination of IC 50 , cells were exposed continuously for four days to varying concentrations of drug in triplicate wells, each seeded with 1500 cells. Each assay was performed with a control that did not contain any drug. The MTT assays were performed at the end of the fourth day.
